방사면역측정에서 방사성 동위원소 표식법 개발에 관한 연구 : 제1편. Human Thyrotropin 의 온화한 조건하 125I-표지를 위한 새로운 방법 Part 1. A New Method for the 125I-Labelling of Human Thyrotropin under Mild Cenditions

조보연,서정헌,박영자,고창순,김병국 대한핵의학회 1981 핵의학 분자영상 Vol.15 No.2

125I-Labelling of human thyrotropin (h-TSH) Was performed using a small amount of chloramine T(CT) as an oxidant at room temperature. When compared with the conventional method that uses a large amount of CT, this method facilitated uniform labelling and reduced the damage of h-TSH by CT, a strong oxidizing reagent. h-TSH* prepared by the new method was comparable to the commercial product of Daiichi Company, in terms of affinity to antibody and effective period.

쥐 하이브리도마 세포배양을 위한 무혈청 배지개발 (Ⅰ) : 최적 배지성분의 결정 Determination of Optimal Media Composition

조보연,최태부 한국산업미생물학회 1989 한국미생물·생명공학회지 Vol.17 No.5

최근 단일클론항체의 상업적 이용가치가 증대하면서 그 수요량 또한 급격히 증가, 이를 뒷받침할 수 있는 대량생산 기술이 요구되고 있다. 본 연구에서는 쥐 하이브리도마 Alps 25-3의 대량배양을 위해 우선적으로 무혈청 배지(serum-free media)의 개발을 시도하였다. 동물세포 배양액 IMDM과 Ham's F-12를 1:1로 혼합한 배지를 기본으로하여 ITES용액(insulin 10 ㎍/㎖, transferrin 10 ㎍/㎖, ethanolamine 10 μM and selenium 30 nM)을 첨가하여 일차적으로 결정한 EBM(enriched basal medium)에 steroid hormones, vitamins, lipid, mineral 및 여러 성분들을 각각 첨가하여 혈청과 대치될 수 있는 성분들의 최적농도를 조사하였다. 각 성분들의 개별 효과와 함께 그들을 혼합하였을 때의 상호효과를 통해 혈청배지와 거의 동일한 성장을 보이는 무혈청배지 KM3(EBM with BSA 100 ㎍/㎖, mineral solution and 0.05% PEG)를 결정할 수 있었으며 이 배지에서의 최고 항체 생성량은 혈청배지의 약 80%로 나타났다. 또한 무혈청 배지에서 여러 cell line의 성장과 그들의 항체 생성을 조사함으로써 다른 쥐 하이브리도마 세포배양에도 적용시킬 수 있음을 확인할 수 있었다. A serum-free medium that could be used for the large-scale culture of mouse hybridoma to produce monoclonal antibodies was developed. The medium was based on a 1:1 mixture of Iscove's Modified Dulbecco's Medium and Ham's F-12, supplemented with insulin 10 ㎍/㎖, transferrin 10 ㎍/㎖, ethanolamine 10 μM and selenium 30 nM(designated EBM (enriched basal medium) with the supplements). The effect of various supplements of steroid hormones, vitamins, lipid and mineral salts was investigated and their optimal concentration was determined to replace fetal calf serum (FCS). These components were added respectively and then added by way of two or three combination to discern of which component combination was effective to the culture of hybridoma. As a result, serum-free medium KM3(EBM with BSA 100 ㎍/㎖, mineral cocktail and 0.05% PEG) was determined. The hybridoma Alps 25-3 cultured in this medium showed almost the same growth rate as in medium added with 2% fetal bovine serum. However, the antibody concentration from KM3 cultures was 80% of that obtained from culture with FCS. KM3 was also examined for the culture of other mouse hybridomas, KW, A4W & HCGK, and it was confirmed that it could support the growth of these hybridomas and the production of monoclonal antibodies.

차단형 TSH 수용체 항체의 작용기전 : 갑상선 세포막 및 수용체 후 신호전달에 미치는 영향 Effects on the Membrane Receptor of Thyrocyte and Post-Receptor Signal Transduction

조보연,이홍규,고창순,민헌기,이동수,송영기,이가희 대한내분비학회 1991 Endocrinology and metabolism Vol.6 No.1

To evaluate mechanisms of action of blocking type-TSH receptor antibody in patients with prmary nongoitrous hypothyroidism, we studied the effects of IgGs form 17 patients with primary nongoitrous hypothyroidis, on 3H-thymidine incorporation into rat thyroid cells, FRTL-5, induced by TSH, Graves' IgG, dibutyl cAMP (dBcAMP), forskolin, and insulin-like growth factor I (IGF-I). IgGs from 11 out of 12 patients with primary nongoitrous hypothyroidism who had TBII activities inhibited both TSH- and Graves' IgG-stimlated 3H-thymidine incorporation in a dose-dependent manner. dBcAMP, forskolin, and IGF-I stimulated 3H-thymidine incorporation into FRTL-5 cells dose-dependently. However, all IgGs from 17 patients with primary nongoitrous hypothyroidism did not inhibit 3H-thymidine incorporation induced by dBcAMP (10-4M), forskolin (10-4M), and IGF-I (10ng/ml)in the range of 0.5-10 mg/ml IgG. The synergistic effect of coincubation with IGF-I (10 ng/ml) and TSH (1 mU/ml) or Gravrs' IgG (5 mg/ml) on 3H-thymidine incorporation into FRTL-5 cells disappeared by IgGs from patients with primary nongoitrous hypothyroidism. However, the proportion of 3H-thymidine incorporation induced by IGF-I itself was not inhibited by these IgGs. These frsults suggest that blocking type-TSH receptor antibody dose not affect post-receptor signal transduction and action of IGF-I. Therefore, the inhibitory action of blocking type-TSH receptor antibody may be on the-TSH receptor level through the inhibition of TSH binding to the TSH recptor. (J Kor Soc Endocrinol 6:8 16, 1991)

위축성 자가면역성 갑상선염 ( 일차성 점액수종 ) 환자에서 항갑상선제 투여후 차단형 갑상선 자극호르몬 수용체 항체의 변화

조보연,이홍규,신찬수,김원배,고창순,김성연,정재훈 대한내분비학회 1995 Endocrinology and metabolism Vol.10 No.3

It is well Known that antithyroid drug treatment of Graves' disease suppresses excessive thyroid hormone synthesis and causes a parallel decrease in serum thyroid autoantibody levels including thyroid stimulating antibodies(TSAb) in most patients suggesting the immunosuppressive or immunomodulating effects of antithyroid drugs. In the context of view that thyrotropin receptor blocking antibody may play an important pathogenetic role at least in some patients with primary myxedema(chronic atrophic autoimmune thyroiditis), antithyroid drug treatment in these patients might be beneficial to disease course. To evaluate the effect of antithyroid drug on the thyrotropin receptor blocking antibody levels, we serially measured thyrotropin-binding inhibitor immunoglobulins(TBII) and thyroid stimulation blocking antibodies(TSBAb) using FRTL-5 cells, antimicrosomal- and antithyroglobulin antibody activities in 7 patients with primary myedema who have blocking TSH receptor antibodies during 6 months of methimazole(MMI, 40mg/day) administration. TBII and TSBAb activities did not change after MMI, but one of them showed stepwise decrease and disappearance of TBII and TSBAb activities. Antimicrosomal- and antithyroglobulin antibody activities decreased significantly after 3 months of MMI administration in those patients. These results suggest a minimal effect of antithyroid drug treatment on the level of thyrotropin receptor blocking antibodies. Persistence of thyrotropin receptor blocking antibodies despite of the decrease in antimicrosomal and antithyroglobulin antibodies might suggest that blocking TSH receptor antibodies of primary myxedema is produced mainly in extrathyroidal tissue in contrast to the thyroid stimulating antibodies of Graves' disease. One patient, whose blocking antibody have disappeared after MMI treatment, is under observation to see if she will remain in remission of hypothyroidism(J Kor Soc Endocrinol 10: 229-241, 1995).

99m Tc-Methylene Diphosphonate (MDP) 골스캔에서 골격외 섭취 및 신요로계 이상소견에 관한 연구

조보연,이명철,이홍규,고창순,김병태,임상무,박난재 대한핵의학회 1982 핵의학 분자영상 Vol.16 No.1

갑상선질환에서의 핵의학적 이용

조보연 한국의학사 1985 診斷과治療 Vol.5 No.2

갑상선기능항진증 분야의 20세기 회고 및 21세기 전망

조보연 대한갑상선-내분비외과학회 2001 The Koreran journal of Endocrine Surgery Vol.1 No.1

'스콜라' 이용 시 소속기관이 구독 중이 아닌 경우, 오후 4시부터 익일 오전 7시까지 원문보기가 가능합니다.

Scintigraphic Demonstration of Bronchopleural Fistula

조보연,고창순,오연상,박석근,정연태 대한핵의학회 1985 핵의학 분자영상 Vol.19 No.1

일차성 점액수종 환자의 IgG 아형에 따른 TSH 수용체 항체 활성의 분포와 항 - IgG 항체에 의한 차단형 IgG 아형의 자극형 항체로의 전환

조보연,김영건,정재훈,송민호,노흥규 대한내분비학회 1993 Endocrinology and metabolism Vol.8 No.2

We previously reported that IgGl was the most important subclass containing TSH receptor blocking anitbody activity but clearaly detectable blocking activity was found in the IgG2, IgG4, We tried to confirm the IgG subclass distribution of TSH receptor blocking antibody activity by measuring the TSH binding inhibitory immunoglobulin in the purified IgG subclass fractions and by converting the TSH receptor bound blocking type IgG subclass to the stimulating type by antihuman IgG antibody (Fab specific) in rat thyroid (FRTL-5) cells. From four patients with primary nongoitrous hypothyroidism, sera containing TSH receptor blocking activity were separated into four IgG subclasses and non IgG fraction by deletion affinity chromatography using affinity columns of subclass specific monoclonal antibodies. The TBII activities were dominant in IgG1 fractions in all four patients, but IgG2 and IgG4, fractions also showed significant TBII activites compared to non-IgG fractions in 2 patients. The significant amount of cAMP production after the addition of gaoat antihuman IgG antibody (Fab specific) to the IgG subclass (TSH receptor blocking antibody) bound FRTL-5 cells was noted in IgG1, IgG2, IgG4 frations in cases 1, in IgG1, IgG2, fractions in case 2, in IgG1 fraction in case 3, in IgG1, IgG4 fractions in case 4. These findings support the previous our study on the unrestricted IgG subclass distribution of TSH receptor blocking antibldies in primary nongoitrous hypothyroidism. (J Kor Soc Endocrinol 8:164~170, 1993)

당뇨병 유발백서의 초기 신장비대와 신장조직 IGF-Ⅰ

조보연,이홍규,고창순,민헌기,김성연,홍성관,고경수,이병두,장학철 대한당뇨병학회 1990 Diabetes and Metabolism Journal Vol.14 No.1